Session Type: Poster Session (Monday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60% of patients (pts) with AS, respectively.1-5 Early and sustained relief of these symptoms are essential for effective AS management.4,6 Secukinumab (SEC) provided sustained relief in pain and fatigue in AS pts over 2 years in the MEASURE 2 study.7 Here we report the effect of subcutaneous (s.c.) SEC 150mg on key clinical symptoms (pain, morning stiffness, and fatigue) in pts with AS over 208 weeks (wks) in the MEASURE 2 study.
Methods: The MEASURE 2 study design has been reported previously. This post hoc analysis assessed the mean change from baseline at Week (Wk) 208 in total and nocturnal back pain scores (by visual analog scale [0–100]; ASAS outcome component), overall level of spinal pain (neck, back, or hip) from BASDAI score, and morning stiffness (overall level; mean of question 5 and 6 of BASDAI score). Additionally, the SF-36 physical component summary (PCS) score, overall level of fatigue (BASDAI question 1), FACIT-Fatigue score, and pts meeting minimal clinically important difference (MCID) criteria across multiple clinical domains were also assessed. Data are shown for pts originally randomized to SEC 150mg and placebo. Data are reported as observed for overall population and by prior anti-TNF therapy status (naïve vs inadequate response/intolerance [IR]).
Results: Baseline clinical characteristics were generally comparable across the treatment groups SEC 150mg (N=72) and placebo (N=74); total mean back pain score was 67.7±17.79, nocturnal back pain score (0–100 mm scale) was 64.9±19.58, and morning stiffness was 6.5±2.11. SEC 150mg-treated pts reported rapid and early reductions in pain scores by Wk 4, which were sustained through Wk 208 (Table). Improvements with SEC 150mg were also reported in nocturnal back pain, morning stiffness, physical function (SF-36 PCS) and fatigue (overall level of fatigue and FACIT-Fatigue) as early as Wk 4, which were sustained at Wk 208 (Table). A higher proportion of SEC 150mg-treated pts met MCID criteria at Wk 16 vs placebo across multiple clinical domains, which was sustained or further improved through Wk 208. Improvements were observed in both anti-TNF-naïve and -IR pts, with a greater magnitude of improvement in anti-TNF-naïve pts.
Conclusion: SEC 150mg was associated with rapid and clinically meaningful improvement in total back pain and nocturnal back pain, morning stiffness, and fatigue, with improvements sustained over 4 years of treatment.
- Ward MM, et al. Arthritis Care Res. 1999;12:247-55.
- Calin A, et al. J Rheumatol. 1993;20:991-5.
- Jones SD, et al. J Rheumatol. 1996;23:487-90.
- Aissaoui N, et al. Rheumatol Int. 2012;32:2117-24.
- Steven DW. Atlas of Uncommon Pain Syndromes (3rd edition). 2014;chapter-79:230.
- Brophy S, et al. Semin Arthritis Rheum. 2013;42:361-7.
- Deodhar A, et al. Clin Exp Rheumatol. 2019;37:260-9.
To cite this abstract in AMA style:Marzo-Ortega H, Miceli-Richard C, Gill S, Magrey M, Machado P, Shete A, Wang J, Rohrer S, Deodhar A. Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/subcutaneous-secukinumab-150-mg-provides-rapid-and-sustained-relief-in-total-and-nocturnal-back-pains-morning-stiffness-and-fatigue-in-patients-with-active-ankylosing-spondylitis-over-4-years/. Accessed January 30, 2023.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-secukinumab-150-mg-provides-rapid-and-sustained-relief-in-total-and-nocturnal-back-pains-morning-stiffness-and-fatigue-in-patients-with-active-ankylosing-spondylitis-over-4-years/